Immune checkpoint inhibition and its relationship with hypermutation phenoytype as a potential treatment for Glioblastoma

Glioblastoma (GBM) is the most common malignant brain tumour in adults. Current prognosis with standard treatment is poor. Immunotherapy is a new paradigm in tumour management. Specifically, recent advances in the field of immune checkpoint molecules have led to dramatic results in many cancers. Inh...

Ausführliche Beschreibung